Expect a rerate, page-38

First 38 Last

Share
Profile

Follow
ryan4321

683 Posts.

223

30/08/21

17:29

Post #: 55688629
Share

Originally posted by Autosime: ↑

Ryan
sometimes you have to simplify the argument

I bought in the low 1s as I posted and sold at may target circa 30% gain which I had also posted was my exit target. I made the case it was relatively undervalued .in the low 1s which the market still agrees with as its now 1.30. You posted it wasn’t while claiming MSB had so much upside which is now even lower. Our return are about 40% apart
30% vs
-10%

I have moved on from this and only came back to the thread because I was tagged into a post on what has proven to be a small sharp sell down with the stock bouncing back the next day.

it’s amazing you and ksvs are seeking to argue a case when on a return point of view I have been clearly right . The market is dynamic and stocks change on a valuation basis. Once you lock in a return , it’s no longer relevant how the company is going unless you are looking to re-enter so to be honest I haven’t even looked at how they are going as two of their biggest markets are in lockdown and thus on a macro level it will no doubt be tough. I am focusing on stocks I own and stocks I am looking to own . In deciding on how I should invest I incorporate both stock specific news and my view on the macro reality

Expand

You are a trader. Not an investor. So you should not be using the term 'undervalued'.
Oversold is more accurate as I am talking macro on the company and you are taking macro trading short term. Macro means nothing when you are trading such a short time frame.
I am short the company over a long time frame so macro is worth discussing, hence a little frustrated I am conversing on macro with a price action scalper.

A2B Price at posting: $1.30 Sentiment: Sell Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CLE

Cyclone signs MOU with Vale for development of Iron Bear play

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CUF

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

EEG

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

First 38 Last

Add A2B (ASX) to my watchlist

Expect a rerate, page-38

Top Stories

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Cyclone signs MOU with Vale for development of Iron Bear play

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

HotCopper Highlights: Your most watched stocks for Week 46, 2024

Banshee's historic trenches prove rich in antimony and gold for GDM

Featured News